Sanofi to expand immunology offerings with Blueprint Medicines
Pharmaceutical Technology
JUNE 2, 2025
Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Pharmaceutical Technology
JUNE 2, 2025
Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.
Bio Pharma Dive
JUNE 18, 2025
With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of disease-causing genetic mutations in conditions like epilepsy and Charcot-Marie-Tooth disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 3, 2025
As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the pharmaceutical industry.
Pharmaceutical Technology
MAY 22, 2025
Orionis Biosciences has announced a multi-year partnership with Roches Genentech for small-molecule monovalent glue medicine.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine.
Bio Pharma Dive
MAY 15, 2025
A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months.
Bio Pharma Dive
JUNE 18, 2025
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.
Bio Pharma Dive
JUNE 27, 2024
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.
Bio Pharma Dive
MAY 12, 2025
Explore the cutting-edge of science and learn how Danaher is advancing healthcare innovation
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research.
Pharmaceutical Technology
MAY 26, 2025
The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSKs Blenrep.
Scienmag
JUNE 10, 2025
In a groundbreaking development that promises to accelerate drug discovery and pharmaceutical research, Insilico Medicine, a leading clinical-stage biotechnology company harnessing generative artificial intelligence, has announced the launch of its latest foundation model, Nach01, on Amazon Web Services (AWS).
Bio Pharma Dive
JUNE 11, 2025
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
Pharmaceutical Technology
MAY 9, 2025
HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.
Bio Pharma Dive
JULY 15, 2024
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
Bio Pharma Dive
JUNE 17, 2025
The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong in decline in Verve’s share price amid skepticism over the need for such a therapy.
Bio Pharma Dive
MAY 6, 2025
A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
Bio Pharma Dive
MAY 15, 2025
ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.
BioTech 365
JUNE 23, 2025
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept) European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept) REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a … Continue reading →
Medical Xpress
JUNE 16, 2025
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ipilimumab (NIVO+IPI)—in the treatment of liver cancer patients since 2016.
Rethinking Clinical Trials
MAY 12, 2025
Hernandez, who serves as coprincipal investigator of the NIH Pragmatic Trials Collaboratory Coordinating Center, is a professor of medicine and vice dean in the Duke University School of Medicine and executive director of the Duke Clinical Research Institute. Spaeder is the chief medical and scientific officer at IQVIA.
Rethinking Clinical Trials
NOVEMBER 13, 2024
Delgado is an associate professor of emergency medicine and epidemiology at the University of Pennsylvania and the director of the Penn Medicine Nudge Unit, which “designs and implements scalable nudges to improve medical decision-making and patient outcomes.” ” Join the online meeting.
Rethinking Clinical Trials
DECEMBER 11, 2024
Gbenga Ogedegbe In this Friday’s PCT Grand Rounds, Gbenga Ogedegbe of the NYU Grossman School of Medicine will present “Home Blood Pressure Telemonitoring and Nurse Case Management in Black and Hispanic Patients With Stroke: A Randomized Clinical Trial.” Join the online meeting.
Pharmaceutical Technology
MAY 28, 2025
The US FDA has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta Pharmas C-CAR168.
Bio Pharma Dive
MAY 2, 2025
Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.
Bio Pharma Dive
JUNE 17, 2025
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.
Rethinking Clinical Trials
FEBRUARY 12, 2025
Volandes is a professor of medicine at the Geisel School of Medicine at Dartmouth and the vice chair for research in the Department of Medicine at Dartmouth Health. Tulsky is a professor of medicine at Harvard Medical School and the Poorvu Jaffe Chair of Supportive Oncology at the Dana-Farber Cancer Institute.
Bio Pharma Dive
OCTOBER 22, 2024
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
STAT News
JUNE 20, 2025
The study, presented Friday at the American Diabetes Association’s scientific meeting and simultaneously published in the New England Journal of Medicine , updates previous research that followed these participants for a shorter period of time. After 12 months, out of the 12 participants, 10 no longer needed to inject insulin.
Medical Xpress
MARCH 7, 2025
Published in npj Regenerative Medicine, the study reveals a novel approach to promoting cardiomyocyte proliferation. DeBakey Department of Surgery at Baylor College of Medicine, the QIMR Berghofer Medical Research Institute in Brisbane, Australia, and collaborating institutions. The researchers are from the Michael E.
Bio Pharma Dive
SEPTEMBER 4, 2024
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
Rethinking Clinical Trials
APRIL 2, 2025
Heerman is an associate professor of internal medicine and pediatrics, the William K. Warren Foundation Chair in Medicine, and chief of the Division of Academic General Pediatrics at Vanderbilt University Medical Center. ” The Grand Rounds session will be held on Friday, April 4, 2025, at 1:00 pm eastern. Join the online meeting.
Pharmaceutical Technology
MAY 12, 2025
The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.
Rethinking Clinical Trials
MARCH 19, 2025
Blood is an instructor of medicine and associate director of the Accelerator for Clinical Transformation Research Group at Harvard Medical School and a cardiologist and intensivist at Brigham and Women’s Hospital. ” The Grand Rounds session will be held on Friday, March 21, 2025, at 1:00 pm eastern.
Rethinking Clinical Trials
JANUARY 29, 2025
Skolasky is a professor of orthopaedic surgery and the director of the Spine Outcomes Research Center, and McLaughlin is an assistant professor of physical medicine and rehabilitationboth at the Johns Hopkins University School of Medicine. Join the online meeting.
Bio Pharma Dive
JUNE 9, 2025
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, might have effects that last at least four weeks.
Bio Pharma Dive
JANUARY 7, 2025
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
Rethinking Clinical Trials
JANUARY 8, 2025
Join the online meeting.
Bio Pharma Dive
APRIL 8, 2024
But many development hurdles still stand in the way of new medicines for the brain. Recent biotech company acquisitions have put emerging schizophrenia treatments in focus.
Pharmaceutical Technology
MAY 2, 2025
4D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for 4D-150.
Bio Pharma Dive
NOVEMBER 14, 2024
The company is paying China-based biotech LaNova Medicines $588 million for the type of dual-pronged antibody drug that recently bested Keytruda in a clinical trial.
Bio Pharma Dive
JULY 11, 2024
Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.
Bio Pharma Dive
NOVEMBER 21, 2024
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.
Bio Pharma Dive
SEPTEMBER 23, 2024
With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content